TLR4 and congenital rubella syndrome: Therefore, the combination of TLR4 inhibitor and TNF-α neutralizing antibody may represent a promising therapeutic strategy in treating CRS in patients of COVID-19 and other syndromes, such as CAR-T cell anti-tumor therapy, where CRS is a common side effect.